• Explore /
  • Poster
  • / Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.

Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.

Abstract Poster

Authors

Kei Muro

Kei Muro

Aichi Cancer Center Hospital, Nagoya, Japan

Kei Muro , Keisho Chin , Steven Brad Maron , Fadi S. Braiteh , Seiichiro Mitani , Hiroki Hara , Yasutoshi Kuboki , Mary F Mulcahy , Joaquina Celebre Baranda , Faithlore Patrice Gardner , Ning Jin , Satoshi Hamauchi , Jason Kaplan , Seema Rao Gorla , Shubin Liu , Michele Wozniak , Changting Meng , Shunsuke Kondo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04225117

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4046)

DOI

10.1200/JCO.2024.42.16_suppl.4046

Abstract #

4046

Poster Bd #

26

Abstract Disclosures

Similar Posters

First Author: Anthony B. El-Khoueiry

First Author: Wei Li

First Author: Junsheng Wang

First Author: Michael J. Overman